MedTrace Logo

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

NCT01518309 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2020-11-23

Study results available
· View outcomes & findings →

Summary

This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).

Conditions

  • Parkinson's Disease Psychosis

Interventions

DRUG

pimavanserin tartrate (ACP-103)

Tablets taken once daily by mouth at 20, 40, or 60 mg doses

Sponsors & Collaborators

  • ACADIA Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-17
Primary Completion
2013-05-02
Completion
2013-05-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01518309 on ClinicalTrials.gov